ArticleJournal of visualized experiments : JoVE2025
Mapping Dysfunctional Protein-Protein Interactions in Disease.
Anna Rodina, Hediye Erdjument-Bromage, Mara Monetti, Zhuoning Li, Souparna Chakrabarty, Shujuan Wang, Chander S Digwal, Laura Tuffery, Palak Panchal, Sahil Sharma and 3 more
Abstract readVideo-Audio Media
In one paragraphArticle in Journal of visualized experiments : JoVE, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Anna Rodina *Chemical Biology Program, Memorial Sloan Kettering Cancer Center.
Hediye Erdjument-Bromage *Department of Neuroscience and Physiology, NYU Grossman School of Medicine.
Mara MonettiProteomics Core, Memorial Sloan Kettering Cancer Center.
Zhuoning LiProteomics Core, Memorial Sloan Kettering Cancer Center.
Souparna ChakrabartyChemical Biology Program, Memorial Sloan Kettering Cancer Center.
Shujuan WangChemical Biology Program, Memorial Sloan Kettering Cancer Center.
Chander S DigwalChemical Biology Program, Memorial Sloan Kettering Cancer Center.
Laura TufferyProteomics Core, Memorial Sloan Kettering Cancer Center.
Palak PanchalChemical Biology Program, Memorial Sloan Kettering Cancer Center.
Sahil SharmaChemical Biology Program, Memorial Sloan Kettering Cancer Center.
Tanaya RoychowdhuryChemical Biology Program, Memorial Sloan Kettering Cancer Center.
Thomas A NeubertDepartment of Neuroscience and Physiology, NYU Grossman School of Medicine; NYU Neuroscience Institute, NYU Grossman School of Medicine.
Gabriela ChiosisChemical Biology Program, Memorial Sloan Kettering Cancer Center; Department of Medicine, Division of Solid Tumors, Memorial Sloan Kettering Cancer Center; chiosisg@mskcc.org.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MProject 3: Structural Basis for grp94 Drug Development and Chaperone FunctionP01CA186866 · NCI · OHIO STATE UNIVERSITY · PI LI, ZIHAI · 2015 to 2019
$6.7MImpact of sex differences on the trajectory of interactome dysfunctions across the AD spectrumR01AG074004 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, GINSBERG, STEPHEN D · 2021 to 2025
$6.0MChaperome networks in Alzheimer's diseaseR01AG067598 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI ARANCIO, OTTAVIO, CHIOSIS, GABRIELA · 2021 to 2025
$5.9MSelective interactome vulnerability across the Alzheimer’s disease spectrumR01AG072599 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI GABRIELA CHIOSIS, STEPHEN D GINSBERG · 2023 to 2026
$5.4M[18F]-PU-AD epichaperome PET imaging probeRF1AG071805 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, DUNPHY, MARK P. · 2022 to 2025
$4.8MSmall molecule Hsp90 inhibitors in AD treatmentU01AG032969 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2010 to 2014
$3.5MBiomarkers for predicting response to Hsp90 therapyR01CA172546 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, DUNPHY, MARK P. · 2013 to 2017
$2.9MTargeting the heat shock response for the therapy of DLBCLR01CA155226 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHIOSIS, GABRIELA, MELNICK, ARI M. · 2011 to 2015
$2.5MA chemical chaperomics platform for ADR56AG061869 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA · 2018 to 2019
$1.8MSelective interactome vulnerability across the Alzheimer’s disease spectrumR56AG072599 · NIA · SLOAN-KETTERING INST CAN RESEARCH · PI CHIOSIS, GABRIELA, GINSBERG, STEPHEN D · 2021 to 2021
$1.2MLTQ-Orbitrap Mass Spectrometer.S10RR027990 · NCRR · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NEUBERT, THOMAS A · 2011 to 2011
$600kNCI NIH HHS P01 CA186866NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA155226NCI NIH HHS R01 CA172546NCRR NIH HHS S10 RR027990NIA NIH HHS R01 AG067598NIA NIH HHS R01 AG072599NIA NIH HHS R01 AG074004NIA NIH HHS R56 AG061869NIA NIH HHS R56 AG072599NIA NIH HHS RF1 AG071805NIA NIH HHS U01 AG032969
6 · The paper itselfAbstract
Protein-protein interaction (PPI) networks are dynamically remodeled in disease, yet most systems biology approaches focus on changes in protein abundance, overlooking critical interaction-level dysfunction. Here, we present a robust, chemoproteomic method-dysfunctional Protein-Protein Interactome (dfPPI)-that enables high-throughput, systematic, disease-contextual mapping of PPI network dysfunctions in cells and primary human tissue. This method integrates chemical biology probes that selectively capture epichaperome-based interactome assemblies with label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS) and network-based computational analysis, to uncover the rewiring of protein networks not apparent from transcriptomic or proteomic data alone. The dfPPI platform can be applied across disease states, species, and tissues to identify actionable nodes of dysfunction and enable high-resolution, systems-level insights into disease progression. In this protocol, we demonstrate step-by-step procedures for sample preparation, chemical probe treatment, affinity enrichment, label-free LC-MS/MS analysis, and bioinformatics workflows used to generate and interpret dfPPI datasets. This article aims to promote reproducibility and accessibility of this approach, supporting its adoption by the broader systems biology and translational research communities.
Indexed as
Protein Interaction MappingProteomicsChromatography, LiquidHumansTandem Mass Spectrometry
Identifiers
PMID41212835
PMCPMC12890052
What Socratic holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390